Kelly Knupp
Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 41 | 2026 | 253 | 8.710 |
Why?
| | Epilepsies, Myoclonic | 36 | 2026 | 63 | 8.580 |
Why?
| | Spasms, Infantile | 26 | 2025 | 138 | 7.080 |
Why?
| | Lennox Gastaut Syndrome | 10 | 2026 | 21 | 5.370 |
Why?
| | Fenfluramine | 13 | 2026 | 20 | 3.540 |
Why?
| | Epilepsy | 21 | 2026 | 400 | 3.480 |
Why?
| | Seizures | 31 | 2026 | 489 | 3.340 |
Why?
| | Vigabatrin | 10 | 2025 | 19 | 2.660 |
Why?
| | Adrenocorticotropic Hormone | 8 | 2025 | 145 | 2.480 |
Why?
| | Electroencephalography | 13 | 2026 | 576 | 1.750 |
Why?
| | Epilepsies, Partial | 5 | 2025 | 62 | 1.450 |
Why?
| | Drug Resistant Epilepsy | 8 | 2025 | 145 | 1.440 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 10 | 2026 | 25 | 1.400 |
Why?
| | Epilepsy, Generalized | 3 | 2023 | 24 | 1.060 |
Why?
| | Child, Preschool | 39 | 2026 | 11913 | 1.000 |
Why?
| | Glucocorticoids | 3 | 2020 | 536 | 0.990 |
Why?
| | Caregivers | 7 | 2025 | 1080 | 0.940 |
Why?
| | Developmental Disabilities | 5 | 2025 | 281 | 0.940 |
Why?
| | Delphi Technique | 3 | 2024 | 350 | 0.930 |
Why?
| | Child | 54 | 2026 | 22693 | 0.890 |
Why?
| | Infant | 35 | 2026 | 10114 | 0.880 |
Why?
| | Plant Extracts | 4 | 2020 | 192 | 0.860 |
Why?
| | Prednisolone | 5 | 2025 | 65 | 0.860 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2024 | 11 | 0.840 |
Why?
| | Cannabidiol | 4 | 2022 | 142 | 0.820 |
Why?
| | Genetic Therapy | 2 | 2023 | 303 | 0.740 |
Why?
| | Humans | 98 | 2026 | 146342 | 0.740 |
Why?
| | Treatment Outcome | 25 | 2026 | 11821 | 0.730 |
Why?
| | Status Epilepticus | 5 | 2024 | 71 | 0.730 |
Why?
| | Adolescent | 35 | 2026 | 22557 | 0.650 |
Why?
| | Medical Marijuana | 2 | 2019 | 120 | 0.640 |
Why?
| | Epilepsy, Absence | 3 | 2026 | 12 | 0.630 |
Why?
| | Dioxolanes | 2 | 2020 | 6 | 0.630 |
Why?
| | Sleep | 4 | 2024 | 896 | 0.610 |
Why?
| | Male | 58 | 2026 | 73396 | 0.590 |
Why?
| | Female | 58 | 2026 | 79499 | 0.540 |
Why?
| | Leukomalacia, Periventricular | 1 | 2017 | 9 | 0.520 |
Why?
| | Thyrotropin | 1 | 2017 | 120 | 0.500 |
Why?
| | Practice Guidelines as Topic | 3 | 2026 | 1591 | 0.500 |
Why?
| | Precision Medicine | 1 | 2021 | 462 | 0.500 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 113 | 0.460 |
Why?
| | Disease Progression | 4 | 2025 | 2867 | 0.450 |
Why?
| | Treatment Failure | 1 | 2016 | 361 | 0.450 |
Why?
| | Cannabis | 3 | 2020 | 521 | 0.450 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 320 | 0.440 |
Why?
| | Executive Function | 3 | 2025 | 463 | 0.430 |
Why?
| | Perception | 1 | 2017 | 373 | 0.410 |
Why?
| | Lafora Disease | 1 | 2014 | 1 | 0.410 |
Why?
| | Unverricht-Lundborg Syndrome | 1 | 2014 | 1 | 0.410 |
Why?
| | Prospective Studies | 15 | 2026 | 8123 | 0.400 |
Why?
| | Video Recording | 2 | 2026 | 219 | 0.400 |
Why?
| | Testosterone | 1 | 2017 | 419 | 0.390 |
Why?
| | Myoclonus | 2 | 2023 | 16 | 0.390 |
Why?
| | Oligonucleotides, Antisense | 2 | 2026 | 122 | 0.390 |
Why?
| | Migraine Disorders | 2 | 2024 | 109 | 0.390 |
Why?
| | Double-Blind Method | 5 | 2026 | 2070 | 0.380 |
Why?
| | Administration, Oral | 5 | 2019 | 872 | 0.380 |
Why?
| | Physicians | 1 | 2021 | 955 | 0.370 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 486 | 0.370 |
Why?
| | Epileptic Syndromes | 5 | 2024 | 98 | 0.340 |
Why?
| | Cost of Illness | 3 | 2018 | 323 | 0.330 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 387 | 0.330 |
Why?
| | Hypertension | 1 | 2019 | 1272 | 0.330 |
Why?
| | Coronavirus Infections | 3 | 2020 | 379 | 0.330 |
Why?
| | Parents | 3 | 2022 | 1394 | 0.310 |
Why?
| | Neurosurgical Procedures | 2 | 2026 | 209 | 0.300 |
Why?
| | Young Adult | 12 | 2026 | 14330 | 0.300 |
Why?
| | Retrospective Studies | 14 | 2025 | 17438 | 0.300 |
Why?
| | Quality of Life | 6 | 2026 | 3200 | 0.290 |
Why?
| | Pandemics | 4 | 2022 | 1707 | 0.280 |
Why?
| | Dronabinol | 3 | 2022 | 251 | 0.270 |
Why?
| | Cognition | 3 | 2025 | 1292 | 0.270 |
Why?
| | Cohort Studies | 8 | 2025 | 6077 | 0.260 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1149 | 0.260 |
Why?
| | Cannabinoids | 2 | 2022 | 182 | 0.260 |
Why?
| | Genetic Testing | 2 | 2023 | 492 | 0.260 |
Why?
| | Biological Ontologies | 1 | 2025 | 21 | 0.220 |
Why?
| | Adult | 14 | 2026 | 41087 | 0.220 |
Why?
| | Headache | 1 | 2006 | 150 | 0.220 |
Why?
| | Smartphone | 1 | 2026 | 103 | 0.220 |
Why?
| | Seizures, Febrile | 1 | 2024 | 23 | 0.220 |
Why?
| | Diet, Ketogenic | 1 | 2025 | 40 | 0.210 |
Why?
| | Dichloroacetic Acid | 1 | 2024 | 7 | 0.210 |
Why?
| | Child Behavior Disorders | 1 | 2026 | 117 | 0.210 |
Why?
| | Delivery of Health Care | 3 | 2020 | 947 | 0.210 |
Why?
| | Vagus Nerve Stimulation | 1 | 2024 | 28 | 0.210 |
Why?
| | Problem Behavior | 1 | 2026 | 97 | 0.210 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.210 |
Why?
| | Analgesics | 1 | 2006 | 230 | 0.200 |
Why?
| | Natural Language Processing | 1 | 2025 | 103 | 0.200 |
Why?
| | Epilepsy, Reflex | 1 | 2023 | 2 | 0.200 |
Why?
| | Comorbidity | 2 | 2019 | 1665 | 0.190 |
Why?
| | Betacoronavirus | 3 | 2020 | 288 | 0.190 |
Why?
| | Lymphocytes | 1 | 2025 | 379 | 0.190 |
Why?
| | Family | 2 | 2018 | 690 | 0.180 |
Why?
| | Wakefulness | 1 | 2024 | 170 | 0.180 |
Why?
| | Animals | 7 | 2026 | 38106 | 0.180 |
Why?
| | Spasm | 1 | 2022 | 21 | 0.180 |
Why?
| | Cosyntropin | 1 | 2022 | 7 | 0.180 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 23 | 0.170 |
Why?
| | Benzazepines | 2 | 2018 | 36 | 0.170 |
Why?
| | Outpatients | 1 | 2025 | 440 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 102 | 0.160 |
Why?
| | Dependovirus | 1 | 2021 | 78 | 0.160 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 20 | 0.160 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 15 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2026 | 5439 | 0.160 |
Why?
| | Standard of Care | 1 | 2020 | 81 | 0.150 |
Why?
| | Internationality | 1 | 2020 | 156 | 0.150 |
Why?
| | Infant, Newborn | 7 | 2024 | 6460 | 0.150 |
Why?
| | Causality | 1 | 2019 | 128 | 0.140 |
Why?
| | Machine Learning | 1 | 2025 | 594 | 0.140 |
Why?
| | Hormones | 1 | 2019 | 134 | 0.140 |
Why?
| | Eyelids | 3 | 2023 | 39 | 0.140 |
Why?
| | Surveys and Questionnaires | 5 | 2026 | 6073 | 0.140 |
Why?
| | Mutation | 3 | 2023 | 4093 | 0.140 |
Why?
| | Drug Approval | 1 | 2019 | 94 | 0.140 |
Why?
| | Health Surveys | 2 | 2018 | 511 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2020 | 541 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 576 | 0.140 |
Why?
| | Phenobarbital | 1 | 2018 | 22 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 997 | 0.130 |
Why?
| | Sickness Impact Profile | 1 | 2018 | 67 | 0.130 |
Why?
| | Urine | 1 | 2017 | 63 | 0.130 |
Why?
| | Incidence | 2 | 2019 | 2936 | 0.130 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2017 | 7 | 0.130 |
Why?
| | United States | 7 | 2019 | 16136 | 0.130 |
Why?
| | Body Height | 1 | 2017 | 205 | 0.120 |
Why?
| | Heterozygote | 1 | 2017 | 311 | 0.120 |
Why?
| | Brain | 3 | 2018 | 2991 | 0.120 |
Why?
| | Employment | 1 | 2018 | 180 | 0.120 |
Why?
| | Neuroimaging | 1 | 2018 | 307 | 0.110 |
Why?
| | Plasma | 1 | 2017 | 222 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2017 | 191 | 0.110 |
Why?
| | Intellectual Disability | 1 | 2017 | 183 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1271 | 0.110 |
Why?
| | Serotonin | 1 | 2017 | 297 | 0.110 |
Why?
| | Neurology | 3 | 2020 | 107 | 0.100 |
Why?
| | Health Care Costs | 1 | 2018 | 423 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2017 | 288 | 0.100 |
Why?
| | Telemedicine | 2 | 2020 | 966 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2018 | 594 | 0.100 |
Why?
| | Body Weight | 1 | 2017 | 968 | 0.100 |
Why?
| | Infant, Premature | 1 | 2017 | 622 | 0.090 |
Why?
| | Colorado | 2 | 2019 | 4595 | 0.090 |
Why?
| | Pentobarbital | 1 | 2011 | 17 | 0.090 |
Why?
| | Age of Onset | 3 | 2018 | 558 | 0.080 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.080 |
Why?
| | Communication | 3 | 2024 | 980 | 0.080 |
Why?
| | Consensus | 2 | 2023 | 467 | 0.080 |
Why?
| | Mental Health | 1 | 2018 | 779 | 0.080 |
Why?
| | Neurologists | 2 | 2021 | 22 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 881 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1143 | 0.080 |
Why?
| | Piracetam | 1 | 2010 | 14 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 729 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 92 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 223 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2363 | 0.070 |
Why?
| | Forecasting | 2 | 2024 | 388 | 0.070 |
Why?
| | Middle Aged | 7 | 2025 | 36619 | 0.070 |
Why?
| | Prevalence | 1 | 2016 | 2861 | 0.070 |
Why?
| | Health Resources | 2 | 2020 | 131 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5899 | 0.060 |
Why?
| | Hyperventilation | 1 | 2026 | 15 | 0.060 |
Why?
| | Post-Dural Puncture Headache | 1 | 2026 | 5 | 0.060 |
Why?
| | Injections, Spinal | 1 | 2026 | 120 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1036 | 0.060 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2005 | 59 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2025 | 75 | 0.050 |
Why?
| | Cell Respiration | 1 | 2025 | 104 | 0.050 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2024 | 10 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1543 | 0.050 |
Why?
| | Oxytocin | 1 | 2005 | 51 | 0.050 |
Why?
| | Europe | 1 | 2026 | 421 | 0.050 |
Why?
| | Maternal Behavior | 1 | 2005 | 83 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2026 | 2022 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2006 | 1503 | 0.050 |
Why?
| | Disease Management | 2 | 2020 | 651 | 0.050 |
Why?
| | Prognosis | 2 | 2026 | 4351 | 0.050 |
Why?
| | Rare Diseases | 1 | 2025 | 117 | 0.050 |
Why?
| | Hyalin | 1 | 2004 | 3 | 0.050 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2004 | 3 | 0.050 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2004 | 4 | 0.050 |
Why?
| | Aggression | 1 | 2005 | 171 | 0.050 |
Why?
| | Wechsler Scales | 1 | 2024 | 60 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 48 | 0.050 |
Why?
| | Introns | 1 | 2024 | 257 | 0.050 |
Why?
| | Social Behavior | 1 | 2026 | 279 | 0.050 |
Why?
| | Signal Transduction | 1 | 2017 | 5246 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2025 | 334 | 0.050 |
Why?
| | Phenotype | 2 | 2025 | 3206 | 0.050 |
Why?
| | Up-Regulation | 1 | 2026 | 841 | 0.050 |
Why?
| | Rectum | 1 | 2004 | 180 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2015 | 3034 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2025 | 721 | 0.040 |
Why?
| | Fatty Acids | 1 | 2025 | 460 | 0.040 |
Why?
| | Pediatrics | 2 | 2020 | 1124 | 0.040 |
Why?
| | Risk Factors | 1 | 2016 | 10921 | 0.040 |
Why?
| | Eosinophils | 1 | 2004 | 319 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2026 | 1998 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2020 | 3926 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 540 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2024 | 930 | 0.040 |
Why?
| | Emotions | 1 | 2026 | 559 | 0.040 |
Why?
| | Health Services | 1 | 2021 | 112 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 453 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 62 | 0.040 |
Why?
| | Internet | 1 | 2024 | 660 | 0.040 |
Why?
| | Tuberous Sclerosis | 1 | 2020 | 56 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2026 | 1763 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 192 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 721 | 0.040 |
Why?
| | Cell Line | 1 | 2025 | 2814 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 115 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1888 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 157 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 120 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 146 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 930 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 145 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2019 | 334 | 0.030 |
Why?
| | Gene Ontology | 1 | 2018 | 55 | 0.030 |
Why?
| | Neurologic Examination | 2 | 2011 | 129 | 0.030 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 2 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 666 | 0.030 |
Why?
| | Critical Illness | 1 | 2024 | 908 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 25 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 3017 | 0.030 |
Why?
| | Waiting Lists | 1 | 2019 | 251 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1203 | 0.030 |
Why?
| | Agenesis of Corpus Callosum | 1 | 2017 | 13 | 0.030 |
Why?
| | Efficiency | 1 | 2018 | 102 | 0.030 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2017 | 24 | 0.030 |
Why?
| | Muscle Hypotonia | 1 | 2017 | 34 | 0.030 |
Why?
| | Receptors, Serotonin | 1 | 2017 | 33 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1734 | 0.030 |
Why?
| | Medicaid | 1 | 2021 | 477 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2017 | 82 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 2017 | 127 | 0.030 |
Why?
| | Income | 1 | 2018 | 206 | 0.030 |
Why?
| | Drug Costs | 1 | 2018 | 116 | 0.030 |
Why?
| | Microcephaly | 1 | 2017 | 106 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 248 | 0.030 |
Why?
| | Larva | 1 | 2017 | 242 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2018 | 314 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 588 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 288 | 0.030 |
Why?
| | Central Nervous System | 1 | 2017 | 278 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 990 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 343 | 0.020 |
Why?
| | Vaccination | 1 | 2022 | 1449 | 0.020 |
Why?
| | Zebrafish | 1 | 2017 | 536 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 902 | 0.020 |
Why?
| | Genetic Variation | 1 | 2017 | 996 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2107 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2244 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 432 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 197 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 790 | 0.020 |
Why?
| | Kidney | 1 | 2017 | 1498 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2488 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1575 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3131 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 1038 | 0.020 |
Why?
| | Hospitalization | 1 | 2018 | 2475 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4580 | 0.010 |
Why?
| | Nalidixic Acid | 1 | 2005 | 1 | 0.010 |
Why?
| | Naphthyridines | 1 | 2005 | 20 | 0.010 |
Why?
| | Fluoxetine | 1 | 2005 | 56 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2786 | 0.010 |
Why?
| | Drug Synergism | 1 | 2005 | 354 | 0.010 |
Why?
| | Submucous Plexus | 1 | 2004 | 2 | 0.010 |
Why?
| | Myenteric Plexus | 1 | 2004 | 4 | 0.010 |
Why?
| | Consanguinity | 1 | 2004 | 50 | 0.010 |
Why?
| | Postpartum Period | 1 | 2005 | 377 | 0.010 |
Why?
| | Aged | 1 | 2022 | 26432 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2005 | 531 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1075 | 0.010 |
Why?
| | Ultrasonography | 1 | 2004 | 788 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2537 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 7109 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5586 | 0.010 |
Why?
| | Neurons | 1 | 2004 | 1668 | 0.010 |
Why?
| | Pregnancy | 1 | 2005 | 7230 | 0.010 |
Why?
|
|
Knupp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|